Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial of Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer (LUST)

NCT05893381 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.

NCT NCT05893381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05893381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial of Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer (LUST)
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2023
Completion date
April 30, 2032
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer